The relation between renal function and serum sclerostin in adult patients with CKD

Clinical Journal of the American Society of Nephrology

Volumn 8, Issue 5, 2013, Pages 819-823

  Pelletier, Solenne ^a   Dubourg, Laurence ^b   Carlier, Marie Christine ^c   Hadj Aissa, Aoumeur ^b   Fouque, Denis ^a  

^a UNIVERSITÉ DE LYON   (France)

^b Service d'Explorations Fonctionnelles Renales et Metaboliques   (France)

^c HOSPICES CIVILS DE LYON   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; PHOSPHATE; SCLEROSTIN; BIOLOGICAL MARKER; BONE MORPHOGENETIC PROTEIN; GENETIC MARKER; SOST PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; BODY MASS; CHRONIC KIDNEY DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; INULIN CLEARANCE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; BLOOD; CASE CONTROL STUDY; CROSS-SECTIONAL STUDY; GENETIC MARKER; KIDNEY; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOPHYSIOLOGY; PROGNOSIS; RENAL INSUFFICIENCY, CHRONIC; SEX DIFFERENCE; UPREGULATION;

ADULT; AGED; BIOLOGICAL MARKERS; BONE MORPHOGENETIC PROTEINS; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; FEMALE; GENETIC MARKERS; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PHOSPHATES; PROGNOSIS; RENAL INSUFFICIENCY, CHRONIC; SEX FACTORS; UP-REGULATION;

EID: 84877641819     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.07670712     Document Type: Article

References (23)

1. van Bezooijen RL, Ten Dijke P, Papapoulos SE, Löwik CW: SOST/ sclerostin, an osteocyte-derived negative regulator of bone formation. Cytokine Growth Factor Rev 16: 319-327, 2005
2. Moester MJ, Papapoulos SE, Löwik CW, van Bezooijen RL: Sclerostin: Current knowledge and future perspectives. Calcif Tissue Int 87: 99-107, 2010
3. Lin C, Jiang X, Dai Z, Guo X, Weng T, Wang J, Li Y, Feng G, Gao X, He L: Sclerostin mediates bone response to mechanical unloading through antagonizing Wnt/beta-catenin signaling. J Bone Miner Res 24: 1651-1661, 2009
4. Rochefort GY, Pallu S, Benhamou CL: Osteocyte: The unrecognized side of bone tissue. Osteoporos Int 21: 1457-1469, 2010
5. McDonald MM, Morse A, Mikulec K, Peacock L, Yu N, Baldock PA, Birke O, Liu M, Ke HZ, Little DG: Inhibition of sclerostin by systemic treatment with sclerostin antibody enhances healing of proximal tibial defects in ovariectomized rats. J Orthop Res 30: 1541-1548, 2012
6. Li X, Ominsky MS, Warmington KS, Morony S, Gong J, Cao J, Gao Y, Shalhoub V, Tipton B, Haldankar R, Chen Q, Winters A, Boone T, Geng Z, Niu QT, Ke HZ, Kostenuik PJ, Simonet WS, Lacey DL, Paszty C: Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of post-menopausal osteoporosis. J Bone Miner Res 24: 578-588, 2009
7. Drüeke TB, Lafage-Proust MH: Sclerostin: Just one more player in renal bone disease? Clin J Am Soc Nephrol 6: 700-703, 2011
8. Cejka D, Jäger-Lansky A, Kieweg H, Weber M, Bieglmayer C, Haider DG, Diarra D, Patsch JM, Kainberger F, Bohle B, Haas M: Sclerostin serum levels correlate positively with bone mineral density and microarchitecture in haemodialysis patients. Neph-rol Dial Transplant 27: 226-230, 2012
9. Guebre-Egziabher F, Bernhard J, Funahashi T, Hadj-Aissa A, Fouque D: Adiponectin in chronic kidney disease is related more to metabolic disturbances than to decline in renal function. Nephrol Dial Transplant 20: 129-134, 2005
10. Dubourg L, Hadj-Aïssa A, Ferrier B: Adaptation of an enzymatic polyfructosan assayto clinical practice. Anal Biochem 405: 266- 268, 2010
11. Gennari L, Merlotti D, Valenti R, Ceccarelli E, Ruvio M, Pietrini MG, Capodarca C, Franci MB, Campagna MS, Calabró A, Cataldo D, Stolakis K, Dotta F, Nuti R: Circulating sclerostin levels and bone turnover in type 1 and type 2 diabetes. J Clin Endocrinol Metab 97: 1737-1744, 2012
12. Amrein K, Amrein S, Drexler C, Dimai HP, Dobnig H, Pfeifer K, Tomaschitz A, Pieber TR, Fahrleitner-Pammer A: Sclerostin and its association with physical activity, age, gender, body composition, and bone mineral content in healthy adults. J Clin Endo-crinol Metab 97: 148-154, 2012
13. Davies MR, Lund RJ, Mathew S, Hruska KA: Low turnover os-teodystrophy and vascular calcification are amenable to skeletal anabolism in an animal model of chronic kidney disease and the metabolic syndrome. J Am Soc Nephrol 16: 917-928, 2005
14. Bellido T: Downregulation of SOST/sclerostin by PTH: a novel mechanism of hormonal control of bone formation mediated by osteocytes. J Musculoskelet Neuronal Interact 6: 358-359, 2006
15. Drake MT, Srinivasan B, Mödder UI, Peterson JM, McCready LK, Riggs BL, Dwyer D, Stolina M, Kostenuik P, Khosla S: Effects of parathyroid hormone treatment on circulating sclerostin levels in postmenopausal women. J Clin Endocrinol Metab 95: 5056-5062, 2010
16. Mirza FS, Padhi ID, Raisz LG, Lorenzo JA: Serum sclerostin levels negatively correlate with parathyroid hormone levels and free estrogen index in postmenopausal women. J Clin Endocrinol Metab 95: 1991-1997, 2010
17. Mödder UI, Clowes JA, Hoey K, Peterson JM, McCready L, Oursler MJ, Riggs BL, Khosla S: Regulation of circulating scle-rostin levels by sex steroids in women and in men. J Bone Miner Res 26: 27-34, 2011
18. Cejka D, Herberth J, Branscum AJ, Fardo DW, Monier-Faugere MC, Diarra D, Haas M, Malluche HH: Sclerostinand Dickkopf-1 in renal osteodystrophy. Clin J Am Soc Nephrol 6: 877-882, 2011
19. Sabbagh Y, Graciolli FG, O'Brien S, Tang W, dos Reis LM, Ryan S, Phillips L, Boulanger J, Song W, Bracken C, Liu S, Ledbetter S, Dechow P, Canziani ME, Carvalho AB, Jorgetti V, Moyses RM, Schiavi SC: Repressionof osteocyte Wnt/b-cateninsignalingisan early event in the progression of renal osteodystrophy. J Bone Miner Res 27: 1757-1772, 2012
20. Mathew S, Lund RJ, Strebeck F, Tustison KS, Geurs T, Hruska KA: Reversal of the adynamic bone disorder and decreased vascular calcification in chronic kidney disease by sevelamer carbonate therapy. J Am Soc Nephrol 18: 122-130, 2007
21. Mödder UI, Hoey KA, Amin S, McCready LK, Achenbach SJ, Riggs BL, Melton LJ, Khosla S: Relation of age, gender, and bone mass to circulating sclerostin levels in women and men. J Bone Miner Res 26: 373-379, 2011
22. McNulty M, Singh RJ, Li X, Bergstralh EJ, Kumar R: Determination of serum and plasma sclerostin concentrations byenzyme-linked immunoassays. J Clin Endocrinol Metab 96: E1159-E1162, 2011
23. Souberbielle JC, Roth H, Fouque DP: Parathyroid hormone measurement in CKD. Kidney Int 77: 93-100, 2010